SYSihyeong Yi

Sihyeong Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sihyeong Yi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modular Synthesis of Pyritide‐Inspired Macrocycles Featuring Bipyridine Motifs

    by Ji Hyae Lee, Sihyeong Yi, Juhyun Bang, Hyun Choi, Seung Bum Park

    Macrocycles represent a promising class of drug‐like scaffolds with unique structural features and the ability to engage challenging targets such as protein–protein interactions. Inspired by structural characteristics of pyritides, we constructed a library of 27 diverse macrocycles via a build/couple/pair approach, enabled by efficient synthesis of bipyridine‐based triaryl building blocks through azaindole cleavage. Kinetic and cheminformatic analyses confirmed both reactivity trends and structural diversity. From this library, we identified a potential ferroptosis inhibitor, 6 p aW , with clear structure–activity relationships, validating our diversity‐oriented synthesis platform. This strategy offers a robust approach to macrocycle library design, expanding opportunities for targeting previously inaccessible biological space.


  • Open Access

    Modular Synthesis of Pyritide‐Inspired Macrocycles Featuring Bipyridine Motifs

    by Ji Hyae Lee, Sihyeong Yi, Juhyun Bang, Hyun Choi, Seung Bum Park

    Macrocycles represent a promising class of drug‐like scaffolds with unique structural features and the ability to engage challenging targets such as protein–protein interactions. Inspired by structural characteristics of pyritides, we constructed a library of 27 diverse macrocycles via a build/couple/pair approach, enabled by efficient synthesis of bipyridine‐based triaryl building blocks through azaindole cleavage. Kinetic and cheminformatic analyses confirmed both reactivity trends and structural diversity. From this library, we identified a potential ferroptosis inhibitor, 6 p aW , with clear structure–activity relationships, validating our diversity‐oriented synthesis platform. This strategy offers a robust approach to macrocycle library design, expanding opportunities for targeting previously inaccessible biological space.


  • Open Access

    Unveiled reactivity of masked diformylmethane with enamines forming resonance-assisted hydrogen bonding leads to di-meta-substituted pyridines

    by Sihyeong Yi, Ji Hyae Lee, Hana Cho, Kannan Vaithegi, Dawon Yi, Sijun Noh, Seung Bum Park

    Pyridine, an essential structure in drug development, shows a wide array of bioactivities according to its substitution patterns. Among the bioactive pyridines, meta-substituted pyridines suffer from limited synthetic approaches despite their significance. In this study, we present a condensation-based synthetic method enabling the facile incorporation of biologically relevant functional groups at the meta position of pyridine. This methodology unveiled the concealed reactivity of 3-formyl(aza)indoles as diformylmethane analogs for synthesizing dissymmetric di-meta-substituted pyridines without ortho and para substitutions. Furthermore, we uncovered resonance-assisted hydrogen bonding (RAHB) as the requirement for the in situ generation of enamines, the key intermediates of this transformation. Successful development of the designed methodology linked to wide applications—core remodeling of natural products, drug–natural product conjugation, late-stage functionalization of drug molecules, and synthesis of the regioisomeric CZC24832. Furthermore, we discovered anti-inflammatory agents through the functional evaluation of synthesized bi-heteroaryl analogs, signifying the utility of this methodology.


  • Open Access

    Unveiling the concealed reactivity of masked diformylmethane with RAHB-assisted enamines leads to dissymmetric di-meta-substituted pyridines

    by Seung Bum Park, Sihyeong Yi, Ji Hyae Lee, Hana Cho, Kannan Vaithegi, Dawon Yi, Sijun Noh

    Pyridine, an essential structure in drug development, shows a wide array of bioactivities according to its substitution patterns. Among the bioactive pyridines, meta-substituted pyridines suffer from limited synthetic approaches despite their significance. In this study, we present a novel synthetic method enabling the facile incorporation of biologically relevant functional groups at the meta position of pyridine. This methodology unveiled the concealed reactivity of 3-formyl(aza)indoles as diformylmethane analogs for synthesizing dissymmetric di-meta-substituted pyridines without ortho and para substitutions. Furthermore, we uncovered resonance-assisted hydrogen bonding (RAHB) as the requirement for the in-situ generation of enamines, the key intermediates of this transformation. Successful development of the designed methodology linked to wide applications—core remodeling of natural products, drug–natural product conjugation, late-stage functionalization of drug molecules, and synthesis of an unprecedented regioisomer of CZC24832. Furthermore, we discovered anti-inflammatory agents through the functional evaluation of synthesized bi-heteroaryl analogs, signifying the utility of this methodology.

  • Open Access

    Synthesis of substituted pyridines with diverse functional groups via the remodeling of (Aza)indole/Benzofuran skeletons

    by Kannan Vaithegi, Sihyeong Yi, Ji Hyae Lee, Begur Vasanthkumar Varun, Seung Bum Park

    Substituted pyridines with diverse functional groups are important structural motifs found in numerous bioactive molecules. Several methodologies for the introduction of various bio-relevant functional groups to pyridine have been reported, but there is still a need for a single robust method allowing the selective introduction of multiple functional groups. This study reports a ring cleavage methodology reaction for the synthesis of 2-alkyl/aryl 3-electron-withdrawing groups (esters, sulfones, and phosphonates) 5-aminoaryl/phenol pyridines via the remodeling of 3-formyl (aza)indoles/benzofurans. Totally ninety-three 5-aminoaryl pyridines and thirty-three 5-phenol pyridines were synthesized showing the robustness of the developed methodology. The application of this methodology further provided a privileged pyridine scaffold containing biologically relevant molecules and direct drug/natural product conjugation with ethyl 2-methyl nicotinate.


  • Rücktitelbild: Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy (Angew. Chem. 18/2023)

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

  • Back Cover: Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy (Angew. Chem. Int. Ed. 18/2023)

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

  • Open Access

    Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

    Modulating target proteins via the ubiquitin‐proteasome system has recently expanded the scope of pharmacological inventions. Stimulator of interferon genes (STING) is an auspicious target for immunotherapy. Seminal studies envisioned the importance of STING as well as the utility of its agonists in immunotherapy outcomes. Herein, we suggest UPPRIS (upregulation of target proteins by protein‐protein interaction strategy) to pharmacologically increase cellular STING levels for improved immunotherapy. We discovered the small molecule SB24011 that inhibits STING‐TRIM29 E3 ligase interaction, thus blocking TRIM29‐induced degradation of STING. SB24011 enhanced STING immunity by upregulating STING protein levels, which robustly potentiated the immunotherapy efficacy of STING agonist and anti‐PD‐1 antibody via systemic anticancer immunity. Overall, we demonstrated that targeted protein upregulation of STING can be a promising approach for immuno‐oncology.


  • Open Access

    Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy

    by Wansang Cho, Solchan Won, Yoona Choi, Sihyeong Yi, Jong Beom Park, Jun‐Gyu Park, Caroline E. Kim, Chintam Narayana, Ju Hee Kim, Junhyeong Yim, et al.

    Modulating target proteins via the ubiquitin‐proteasome system has recently expanded the scope of pharmacological inventions. Stimulator of interferon genes (STING) is an auspicious target for immunotherapy. Seminal studies envisioned the importance of STING as well as the utility of its agonists in immunotherapy outcomes. Herein, we suggest UPPRIS (upregulation of target proteins by protein‐protein interaction strategy) to pharmacologically increase cellular STING levels for improved immunotherapy. We discovered the small molecule SB24011 that inhibits STING‐TRIM29 E3 ligase interaction, thus blocking TRIM29‐induced degradation of STING. SB24011 enhanced STING immunity by upregulating STING protein levels, which robustly potentiated the immunotherapy efficacy of STING agonist and anti‐PD‐1 antibody via systemic anticancer immunity. Overall, we demonstrated that targeted protein upregulation of STING can be a promising approach for immuno‐oncology.


  • Open Access

    Abstract 2585: Targeted protein upregulation strategy potentiates STING agonist immunotherapy

    by Wansang Cho, Solchan Won, Yoona Choi, Jong Beom Park, Jun-Gyu Park, Sihyeong Yi, Caroline E. Kim, Chintam Narayana, Dong-Sup Lee, Seung Bum Park

    As cancer immunotherapy has been emerged as a new pillar of cancer therapy, many strategies modulating host immunity were suggested for cancer treatment. Stimulator of interferon genes (STING) is a promising target for anticancer immunotherapy. However, dysregulated STING expression, or poor pharmacokinetic profiles of STING agonists pose major challenges. Recently, modulating target protein levels via the ubiquitin-proteasome system, such as proteolysis-targeting chimera (PROTAC), has broadened the scope of pharmacological inventions. Herein, we propose UPPRIS (upregulation of target proteins by protein-protein interaction strategy) to overcome these limitations. We discovered the small molecule SB24011 that inhibits STING-E3 ligase interaction, thereby induces the blockade of E3 ligase-mediated STING degradation. As a result, SB24011 enhanced the STING agonist-mediated immune responses by upregulating cellular STING protein level. Thus, co-administration of SB24011 markedly improved the immuno-oncological efficacy of STING agonist cGAMP and anti-PD-1 therapy for tumor regression and robust systemic antitumor response. Taken together, we successfully demonstrated that targeted STING protein upregulation is a promising strategy for cancer immunotherapy. Citation Format: Wansang Cho, Solchan Won, Yoona Choi, Jong Beom Park, Jun-Gyu Park, Sihyeong Yi, Caroline E. Kim, Chintam Narayana, Dong-Sup Lee, Seung Bum Park. Targeted protein upregulation strategy potentiates STING agonist immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2585.